PMID- 37539261
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230805
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 9
IP  - 7
DP  - 2023 Jul
TI  - Efficacy and safety of zonisamide as the first additional treatment in Chinese 
      patients with focal or secondary bilateral tonic-clonic seizures: An 
      observational ,prospective study.
PG  - e17384
LID - 10.1016/j.heliyon.2023.e17384 [doi]
LID - e17384
AB  - BACKGROUND: To evaluate the efficacy and safety of zonisamide (ZNS) as the first 
      additional treatment for focal or secondarily bilateral tonic-clonic seizure 
      (sBTCS). METHODS: A total of 118 patients between 18 and 75 years of age with 
      focal or sBTCS were recruited from multiple hospitals in Shandong province 
      between May 13, 2021, and February 16, 2022. All received ZNS as the first 
      additional treatment after clinical judgment. Seizure frequency, retention, and 
      adverse events (AEs) were assessed 2 and 5 months after the introduction of ZNS. 
      RESULTS: Overall response rates at 2 and 5 months were 79.5% and 75.5%, 
      respectively, whereas seizure-free rates at the same point were 53.6% and 51%, 
      respectively. The review's retention rates at 2 and 5 months were 95% and 86%, 
      respectively. The most common AEs were anorexia with weight loss (11.8%), 
      dizziness (6.9%), and headache (3.9%). CONCLUSIONS: Our real-world study 
      confirmed the efficacy and safety of ZNS as a first-additional treatment for 
      focal or sBTCS in Chinese patients, with a high short-term retention rate.
CI  - (c) 2023 The Authors.
FAU - TingtingYang
AU  - TingtingYang
AD  - Department of Neurology, Qilu Hospital of Shandong University, China.
FAU - CuihuaYan
AU  - CuihuaYan
AD  - Department of Neurology, Qilu Hospital of Shandong University, China.
FAU - Han, Tao
AU  - Han T
AD  - Department of Neurology, Shandong Provincial Hospital, Shandong University, 
      China.
FAU - Huai kuanWu
AU  - Huai kuanWu
AD  - Department of Interventional Medicine, Shandong Provincial Qianfoshan Hospital, 
      Shandong University, China.
FAU - JunjiHu
AU  - JunjiHu
AD  - Department of Neurology, Zibo Changguo Hospital, Zibo Shandong, China.
FAU - YujiaoWu
AU  - YujiaoWu
AD  - Department of Neurology, Qilu Hospital of Shandong University, China.
FAU - Jin, Yang
AU  - Jin Y
AD  - Department of Neurology, Qilu Hospital of Shandong University, China.
FAU - Jiang, Jing
AU  - Jiang J
AD  - Department of Neurology, Qilu Hospital of Shandong University, China.
FAU - Xue wuLiu
AU  - Xue wuLiu
AD  - Department of Neurology, Qilu Hospital of Shandong University, China.
AD  - Institute of Epilepsy, Shandong University, Jinan, China.
LA  - eng
PT  - Journal Article
DEP - 20230620
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10395020
OTO - NOTNLM
OT  - Anti seizure medicine
OT  - Epilepsy
OT  - Focal-onset seizures
OT  - Secondary bilateral tonic-clonic seizure
OT  - Zonisamide
OT  - sBTCS
COIS- The authors declare no conflict of interest.
EDAT- 2023/08/04 06:43
MHDA- 2023/08/04 06:44
PMCR- 2023/06/20
CRDT- 2023/08/04 04:12
PHST- 2022/10/14 00:00 [received]
PHST- 2023/06/11 00:00 [revised]
PHST- 2023/06/15 00:00 [accepted]
PHST- 2023/08/04 06:44 [medline]
PHST- 2023/08/04 06:43 [pubmed]
PHST- 2023/08/04 04:12 [entrez]
PHST- 2023/06/20 00:00 [pmc-release]
AID - S2405-8440(23)04592-9 [pii]
AID - e17384 [pii]
AID - 10.1016/j.heliyon.2023.e17384 [doi]
PST - epublish
SO  - Heliyon. 2023 Jun 20;9(7):e17384. doi: 10.1016/j.heliyon.2023.e17384. eCollection 
      2023 Jul.